Ildong Holdings Co., Ltd.

A000230

KR7000230003

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
8,790 ^KRW	-0.11%		-0.23%	-16.44%

Mar. 14	Ildong Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Ildong Holdings Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Idience Co., Ltd announced that it has received KRW 14.9949886 billion in funding from Ildong Holdings Co., Ltd.

December 29, 2022

On December 30, 2022, Idience Co., Ltd, closed the transaction.

Latest news about Ildong Holdings Co., Ltd.

Ildong Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Ildong Holdings Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Ildong Holdings Co., Ltd.(KOSE:A000230) dropped from S&P Global BMI Index	23-09-18	CI
Ildong Holdings Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Idience Co., Ltd announced that it has received KRW 14.9949886 billion in funding from Ildong Holdings Co., Ltd.	22-12-29	CI
Idience Co., Ltd announced that it expects to receive KRW 14.9949886 billion in funding from Ildong Holdings Co., Ltd.	22-12-20	CI
Ildong Holdings Co., Ltd. announced that it has received KRW 30 billion in funding	22-11-29	CI
Ildong Holdings Co., Ltd. announced that it expects to receive KRW 30 billion in funding	22-11-14	CI
Ildong Holdings Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-13	CI
Ildong Holdings Co., Ltd.(KOSE:A000230) added to S&P Global BMI Index	22-09-19	CI
Ildong Holdings Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-16	CI
Twist Bioscience, Ildong Pharmaceutical Partner to Discover Antibodies for Immuno-Oncology	22-06-30	MT
Idience Co., Ltd announced that it expects to receive KRW 15.0050118 billion in funding from Ildong Holdings Co., Ltd., Yuanta Investment, Kiwoom Securities Co., Ltd., Investment Arm and other investors	22-06-27	CI
Ildong Holdings Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Ildong Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-17	CI
Ildong Holdings Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-15	CI
Ildong Holdings Co., Ltd. acquired 5.18% stake in Ildong Pharmaceutical Co., Ltd. from Il-dong Foods Co. Ltd. and Lee, Keumki for KRW 22.4 billion.	19-02-26	CI
Ildong Holdings Co., Ltd.(KOSE:A000230) dropped from S&P Global BMI Index	17-09-18	CI
Ildong Holdings Co., Ltd.(KOSE:A000230) dropped from KOSPI 200 Index	17-06-08	CI
Ildong Holdings Co., Ltd. completed the acquisition of 19.25% stake in Ildong Pharmaceutical Co., Ltd. for KRW 65.4 billion.	17-03-27	CI
Ildong Holdings Co., Ltd. made a tender offer to acquire an additional 29.14% stake in Ildong Pharmaceutical Co., Ltd. for KRW 98.9 billion.	17-02-05	CI
Ildong Holdings Co Ltd.(KOSE:A249420) added to S&P Global BMI Index	16-08-31	CI
Ildong Pharmaceutical Co., Ltd. completed the Spin-Off of its pharmaceutical business division for KRW 518.3 billion.	16-07-31	CI
Ildong Pharmaceutical Co., Ltd. agreed to spin-off its pharmaceutical business division.	16-03-08	CI
IlDong Pharmaceutical Announces Earnings Results for the Third Quarter of Fiscal 2015	15-10-27	CI

Chart Ildong Holdings Co., Ltd.

Duration

Period

More charts

Ildong Holdings Co., Ltd., formerly Ildong Pharmaceuticals Co., Ltd., is a Korea-based company engaged in the manufacture of pharmaceuticals. The Companyâs products mainly include general drugs and specialty drugs, such as vitamin supplements, digestive medications, vascular medications, probiotics, topical applications, anti-histamines, antipyretics, analgesics, respiratory medications, endocrine medications, psychoneurological medications, dermatological medications, urologic medications, antibiotics and others. It also provides raw materials, such as synthesises, probiotics and others. In addition, through its subsidiaries, it engages in the advertising agency, medical equipment distribution, software development, food processing and other businesses.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ILDONG HOLDINGS CO., LTD.	-16.44%	73.15M
ELI LILLY AND COMPANY	+31.52%	690B
NOVO NORDISK A/S	+24.09%	546B
JOHNSON & JOHNSON	-5.21%	358B
MERCK & CO., INC.	+17.02%	323B
ABBVIE INC.	+5.01%	287B
ASTRAZENECA PLC	+14.06%	235B
NOVARTIS AG	+4.47%	199B
ROCHE HOLDING AG	-10.10%	195B
AMGEN INC.	+3.98%	161B

Other Pharmaceuticals

Ildong Holdings Co., Ltd.

Equities

A000230

KR7000230003

Pharmaceuticals

Idience Co., Ltd announced that it has received KRW 14.9949886 billion in funding from Ildong Holdings Co., Ltd.

Latest news about Ildong Holdings Co., Ltd.

Chart Ildong Holdings Co., Ltd.

Company Profile

Income Statement Evolution

Sector Other Pharmaceuticals